After the IPO of SCHOTT Pharma, the German stock exchange has gained a new billion-dollar company.
• SCHOTT Pharma celebrates its stock market debut
• Initial price above issue price
• Valuation of four billion euros
The SCHOTT Pharma share marked its initial price at 30 euros, bringing subscription profits to IPO investors. The issue price had previously been set at 27 euros. SCHOTT Pharma therefore did not fully exploit the range between 24.50 euros and 28.50 euros. The price range had only been shortened by the banks to 26.50 to 27 euros the evening before, probably in order not to endanger any upward potential on the first day of trading.
Great investor interest
This decision was probably not due to a lack of interest on the part of investors, as the financial institutions reported in advance that the order book was several times oversubscribed.
With the IPO, SCHOTT Pharma will be valued at around four billion euros – based on the offer price, a market valuation of 3.7 to 4.3 billion euros was previously targeted. The IPO plans envisaged the issue of 34.6 million shares, with the free float after the IPO expected to amount to around 23 percent.
Parent company as a profiteer
The primary beneficiary of SCHOTT Pharma’s listing is the parent company, the Mainz-based glass specialist SCHOTT. The newcomer to the stock market itself, the pharmaceutical division of SCHOTT, will not receive any money as part of the IPO, but the parent company wants to remain on board as a major shareholder and support the subsidiary with financial resources.
SCHOTT Pharma wants to continue growing
SCHOTT Pharma is a supplier in the pharmaceutical sector. The company produces packaging; according to SCHOTT, the product range ranges from syringes and cartridges to vials and ampoules, which are made from Type I borosilicate glass and high-quality pharmaceutical polymer.
The almost one billion euros that the parent company SCHOTT will raise as part of the IPO will, among other things, flow into continuing the growth story and achieving climate neutrality at SCHOTT Pharma – the company wants to achieve the latter goal by 2030.
In the first nine months of the 2023 financial year, SCHOTT Pharma generated revenues of 670.1 million euros. At the same time, earnings before interest, taxes, depreciation and amortization were 187.4 million euros. SCHOTT is targeting annual sales growth of ten percent.
Editorial team finanzen.net
Selected leverage products on SCHOTT Pharma
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on SCHOTT Pharma
The leverage must be between 2 and 20
Advertising